SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Top Cited Papers
- 5 September 2019
- journal article
- review article
- Published by Elsevier BV in The Lancet Diabetes & Endocrinology
- Vol. 7 (11), 845-854
- https://doi.org/10.1016/s2213-8587(19)30256-6
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global OutcomesKidney International, 2015
- GFR Decline and Subsequent Risk of Established Kidney Outcomes: A Meta-analysis of 37 Randomized Controlled TrialsAmerican Journal of Kidney Diseases, 2014
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes MellitusCirculation, 2014
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohortsKidney International, 2011
- Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney DiseaseJournal of the American Society of Nephrology, 2007
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesThe New England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyThe New England Journal of Medicine, 2001
- Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal DiseaseAnnals of Internal Medicine, 2001
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyThe New England Journal of Medicine, 1993